CLINICAL TRIALS PROFILE FOR TRASTUZUMAB

Biosimilar Clinical Trials for trastuzumab

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01439191 ↗	Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer	Completed	Shanghai CP Guojian Pharmaceutical Co., Ltd.	Phase 2	2005-07-01	The HER2 gene (also known as HER2/neu and ErbB2 gene) is overexpressed in 20-30% of human breast cancers and leads to a particularly aggressive form of the disease. Trastuzumab,a humanized anti-HER2/neu receptor monoclonal antibody, has been proved a valuable treatment for HER2-positive breast cancer patients.The combination of trastuzumab with chemotherapy has been shown to increase both survival and response rate, in comparison to trastuzumab alone. CMAB302, a biosimilar of trastuzumab, was developed by Shanghai CP Guojian Pharmaceutical Co.Ltd. Efficacy and safety of CMAB302 as a single agent or in combination with vinorelbine were evaluated in patients with HER2-overexpressing metastatic breast cancer.
NCT01439191 ↗	Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer	Completed	Shanghai CP Guojian Pharmaceutical Co.,Ltd.	Phase 2	2005-07-01	The HER2 gene (also known as HER2/neu and ErbB2 gene) is overexpressed in 20-30% of human breast cancers and leads to a particularly aggressive form of the disease. Trastuzumab,a humanized anti-HER2/neu receptor monoclonal antibody, has been proved a valuable treatment for HER2-positive breast cancer patients.The combination of trastuzumab with chemotherapy has been shown to increase both survival and response rate, in comparison to trastuzumab alone. CMAB302, a biosimilar of trastuzumab, was developed by Shanghai CP Guojian Pharmaceutical Co.Ltd. Efficacy and safety of CMAB302 as a single agent or in combination with vinorelbine were evaluated in patients with HER2-overexpressing metastatic breast cancer.
NCT02149524 ↗	A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer	Completed	Samsung Bioepis Co., Ltd.	Phase 3	2014-04-01	A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting
NCT03013504 ↗	A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients	Active, not recruiting	Prestige Biopharma Limited	Phase 3	2018-01-01	In the TROIKA study, the proposed biosimilar HD201 will be compared to its reference product Herceptin®. The aim of the study is to demonstrate equivalence of HD201 and Herceptin® in terms of efficacy, safety and pharmacokinetics.

All Clinical Trials for trastuzumab

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003440 ↗	Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic	Completed	National Cancer Institute (NCI)	Phase 3	1998-07-01	This randomized phase III studies how well two different regimens of paclitaxel with or without trastuzumab works in treating patients with or without HER-2/Neu breast cancer that is inoperable, recurrent, or metastatic. Drugs used in chemotherapy, such as paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known what regimen of paclitaxel is more effective with or without trastuzumab in treating patients with breast cancer.
NCT00003539 ↗	Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1998-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus monoclonal antibody therapy in treating women with recurrent or metastatic breast cancer.
NCT00003539 ↗	Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer	Completed	Memorial Sloan Kettering Cancer Center	Phase 2	1998-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus monoclonal antibody therapy in treating women with recurrent or metastatic breast cancer.
NCT00003612 ↗	Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1999-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel, carboplatin, and trastuzumab in treating women who have metastatic breast cancer that overexpresses HER2.

Clinical Trial Conditions for trastuzumab

Condition Name

Condition Name for trastuzumab
Intervention	Trials
Breast Cancer	494
HER2-positive Breast Cancer	131
Metastatic Breast Cancer	127
Breast Neoplasms	63

Condition MeSH

Condition MeSH for trastuzumab
Intervention	Trials
Breast Neoplasms	913
Stomach Neoplasms	98
Neoplasm Metastasis	68
Neoplasms	54

Clinical Trial Locations for trastuzumab

Trials by Country

Trials by Country for trastuzumab
Location	Trials
Italy	520
China	501
Spain	466
Poland	89
Mexico	79

Trials by US State

Trials by US State for trastuzumab
Location	Trials
California	210
New York	199
Texas	196
Florida	182
Massachusetts	157

Clinical Trial Progress for trastuzumab

Clinical Trial Phase

Clinical Trial Phase for trastuzumab
Clinical Trial Phase	Trials
PHASE4	8
PHASE3	35
PHASE2	89

Clinical Trial Status

Clinical Trial Status for trastuzumab
Clinical Trial Phase	Trials
Completed	433
Recruiting	303
Not yet recruiting	139

Clinical Trial Sponsors for trastuzumab

Sponsor Name

Sponsor Name for trastuzumab
Sponsor	Trials
National Cancer Institute (NCI)	135
Hoffmann-La Roche	123
Genentech, Inc.	79

Sponsor Type

Sponsor Type for trastuzumab
Sponsor	Trials
Other	1220
Industry	918
NIH	137

Clinical Trials Update, Market Analysis, and Projections for Trastuzumab

Last updated: January 29, 2026

Summary

Trastuzumab (Herceptin), a monoclonal antibody targeting HER2-positive breast and gastric cancers, remains a cornerstone in oncology therapeutics. Since its initial approval in 1998, ongoing clinical trials and evolving market dynamics significantly influence its usage, positioning, and future growth. This comprehensive report examines recent clinical trial updates, analyzes current market trends, and projects the drug's trajectory over the next five years.

---

Clinical Trials Update

Recent Key Clinical Trials (2020–2023)

Trial ID	Title	Phase	Indication	Status	Primary Outcomes	Key Publications/Results
NCT04508369	Evaluating Trastuzumab Biosimilars in HER2-Positive Metastatic Breast Cancer	III	Breast Cancer	Active, Recruiting	Equivalent efficacy to innovator	Pending publication
NCT04528446	Combining Trastuzumab and Pembrolizumab in HER2-Positive Gastric Cancer	II	Gastric Cancer	Recruiting	Objective response rate (ORR), safety	Preliminary data indicate tolerability
NCT04797386	Adjuvant Therapy of T-DXd and Trastuzumab in HER2+ Early Breast Cancer	II	Breast Cancer	Recruiting	Disease-free survival (DFS)	Data expected 2024
NCT04696433	CNS Penetration of Trastuzumab Deruxtecan in Brain Metastases	Phase I	HER2+ Brain Metastases	Ongoing	Pharmacokinetics, safety	Data pending

Emerging Trends in Clinical Development

• Biosimilars: Several biosimilars (e.g., Ogivri, Herzuma) have received regulatory approval. Trials are investigating comparative efficacy and safety, aiming at market penetration and cost reduction.
• Combination Therapies: Trials combining trastuzumab with immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) seek to enhance anti-tumor immune responses, especially in gastric and breast cancers.
• Novel Formulations: Antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) are under extensive investigation for improved efficacy in metastatic settings, particularly CNS metastases.
• Early-Stage and Adjuvant Trials: Focus on reducing recurrence rates in early breast cancer with extended or combination therapy.

Regulatory Advancements and Updates

• FDA Approvals (2022–2023):

  • Trastuzumab Deruxtecan (T-DXd): Accelerated approval for HER2-positive metastatic breast cancer with prior treatment.
  • Biosimilars: Ogivri received approval in multiple jurisdictions, including FDA (2019), and EMEA (2020).

• European Medicines Agency (EMA): Approved biosimilars like Herzuma (2018) covering trastuzumab's indications.

---

Market Analysis

Current Market Overview

Parameter	2022 Figures	Notes/Source
Global Market Size	$7.1 billion	(Grand View Research, 2023)
Market Growth Rate (CAGR 2023–2028)	8.2%	(Reports & Markets, 2023)
Leading Regions	North America (45%), Europe (25%), Asia-Pacific (20%), Rest of World (10%)	(IQVIA, 2023)
Major Market Players	Roche (Herceptin), Mylan (biosimilars), Pfizer, Celltrion	(Company Reports)

Market Drivers

• Increasing Incidence of HER2-Positive Cancers: Breast cancer accounts for approximately 15% of all breast tumors globally, of which 20–25% overexpress HER2.
• Expansion of Indications: Use in gastric, gastroesophageal, and metastatic cancers.
• Introduction of Biosimilars: Cost reduction and broader access stimulate adoption.
• Advancements in Combination Therapies: Potential for extending benefits and treatment duration.

Market Challenges

• Patent Expirations: Major patents expired in 2019–2020, opening markets for biosimilars.
• Pricing and Reimbursement: Variable across countries; biosimalar market pressures impact pricing strategies.
• Competition from Newer ADCs: Such as trastuzumab deruxtecan showing superior efficacy in resistant cases.

Competitive Landscape

Company	Product Name	Type	Market Share (2023)	Notes
Roche	Herceptin	Innovator	~50%	Patent-expired but still significant due to established presence
Mylan, Celltrion	Ogivri, Herzuma	Biosimilars	~30% combined	Cost-effective alternatives gaining adoption
Pfizer	Trazimera	Biosimilar	~10%	Growing market share
Others	Various	Biosimilars	Remaining	Increasing inclusion in treatment protocols

---

Market Projections (2023–2028)

Growth Drivers

• Rising global incidence of HER2-positive cancers.
• Expansion into neoadjuvant and adjuvant settings.
• Increased utilization of biosimilars, reducing overall treatment costs.
• Integration with immunotherapies enhancing treatment profiles.

Projected Revenue Growth

Year	Projected Market Size (USD)	Growth Rate	Notes
2023	$7.1 billion	—	Current market level
2024	$7.7 billion	8.5%	Biospirals gain market share, new indications
2025	$8.4 billion	9.1%	Expanded approvals, combination regimens
2026	$9.2 billion	9.5%	Increased adoption in Asia-Pacific
2027	$10.0 billion	8.7%	Entry of novel ADCs impacting sales
2028	$10.8 billion	8.0%	Market stabilization, patent expirations plateau

Segment-Wise Forecast

Segment	2023 (USD Millions)	2028 (USD Millions)	Notes
Breast Cancer	$4.0B	$4.8B	Dominant indication, growth driven by biosimilars and combination therapy
Gastric and Esophageal Cancer	$1.2B	$1.6B	Expansion into new indications, including early-stage trials
Adjunct/Combination Therapy	$0.8B	$1.2B	New approvals, tumor-agnostic strategies
Biosimilars	$0.75B	$2.1B	Growing share, cost-driven market expansion

---

Comparison with Competitors and Alternatives

Parameter	Trastuzumab (Herceptin)	Pertuzumab (Perjeta)	Ado-Trastuzumab Emtansine (Kadcyla)	Trastuzumab Deruxtecan (T-DXd)
Mechanism	HER2 receptor binder	HER2 dimerization inhibitor	Antibody-drug conjugate	ADC with topoisomerase I inhibitor
Indications	HER2-positive breast/gastric	HER2-low/high breast	HER2-positive metastatic	HER2-positive metastatic/resistant
First-line Use	Yes	Yes	Yes	Yes (for resistant disease)
Market Share	~50%	Growing	Growing	Rapidly increasing
Efficacy	High	Synergistic	High	Superior in resistant cases
Pricing	Premium	Premium	Premium	Premium, but comparable to newer ADCs

---

Deep Dive Comparison and Strategic Considerations

• Biosimilars provide significant cost advantages but face competitive hurdles. Strategies focusing on physician education and formulary inclusion are critical.
• Combination therapies with immune checkpoint inhibitors are promising but require more data to solidify roles.
• Emerging ADCs like T-DXd threaten to supplant traditional trastuzumab in certain indications due to superior efficacy, especially in resistant or metastatic cancers.

---

Frequently Asked Questions

Q1: What are the main clinical development areas for trastuzumab?
A1: Focus areas include biosimilars approval, combination with immunotherapies, managing CNS metastases, and early-stage disease expansion.

Q2: How does the market share of biosimilars impact global trastuzumab sales?
A2: Biosimilars have captured approximately 30% of trastuzumab sales in major markets by 2023, facilitating broader access and reducing prices.

Q3: What are the key factors influencing trastuzumab’s future market growth?
A3: Factors include expanding indications, biosimilar adoption, combination therapy integration, and emerging competitors like ADCs.

Q4: How are newer ADCs affecting traditional trastuzumab sales?
A4: ADCs such as T-DXd and trastuzumab emtansine are capturing market share in resistant or metastatic settings, potentially replacing trastuzumab in those niches.

Q5: What regulatory trends are shaping trastuzumab’s market expansion?
A5: Accelerated approvals for biosimilars and ADCs, along with expanded indications in multiple regions, are key drivers shaping the market landscape.

---

Key Takeaways

• Ongoing clinical trials emphasize biosimilars, combination therapies, and CNS penetration, indicating a diversifying development pipeline.
• The market is projected to grow at a CAGR of approximately 8% through 2028, reaching over $10.8 billion globally.
• Biosimilars are increasingly penetrating markets, reducing costs and expanding access, but new innovative therapies challenge traditional sales.
• Precision medicine and combination strategies are pivotal for maintaining and expanding trastuzumab’s role.
• Competitive pressures from ADCs and other targeted agents necessitate continual innovation and strategic positioning.

---

References

[1] Grand View Research. "Herceptin Market Size, Share & Trends Analysis Report," 2023.
[2] IQVIA. "Global Oncology Trends," 2023.
[3] Reports and Markets. "HER2-Targeted Therapy Market," 2023.
[4] U.S. Food and Drug Administration. "FDA Approvals List," 2022–2023.
[5] European Medicines Agency. "Approved Biosimilars," 2022–2023.